CagriSema

CagriSema is a fixed-dose once-weekly subcutaneous combination of cagrilintide 2.4 mg (a long-acting amylin analog) and semaglutide 2.4 mg (a GLP-1 receptor agonist), in Phase 3 development by Novo Nordisk for chronic weight management and type 2 diabetes. The dual amylin + GLP-1 mechanism targets complementary appetite and metabolic pathways. The Phase 3 REDEFINE 1 trial (3,417 adults with obesity without diabetes, 68 weeks) demonstrated 22.7% mean weight reduction using the trial product estimand and 20.4% using the treatment policy estimand, superior to semaglutide alone (16.1%), cagrilintide alone (11.8%), and placebo (3.0%). REDEFINE 2 (1,206 adults with type 2 diabetes) showed 15.7% weight loss versus 3.1% on placebo. Results were published in NEJM in June 2025. Novo Nordisk submitted the FDA NDA on December 18, 2025, with approval expected late 2026 or early 2027.

Background: Why an Amylin + GLP-1 Combination

Amylin and GLP-1 are both gut-brain axis peptides involved in postprandial appetite regulation, but they engage different receptors and signaling pathways:

• GLP-1 (glucagon-like peptide-1): incretin hormone secreted by intestinal L-cells, acts on GLP-1 receptors in pancreas (insulin secretion), brain (satiety, slowed gastric emptying), and liver. The basis of the GLP-1 RA class (semaglutide, liraglutide, dulaglutide, exenatide).
• Amylin: peptide co-secreted with insulin by pancreatic β-cells, acts on amylin receptors in the brainstem area postrema and hypothalamus. Reduces gastric emptying, suppresses glucagon, and reduces meal-related food intake.

The two systems are complementary: GLP-1 reduces hunger primarily through hypothalamic and gastric pathways, while amylin works through brainstem satiety pathways. Combining them was hypothesized to produce synergistic appetite suppression and weight loss exceeding the sum of individual effects.

Cagrilintide is a long-acting amylin analog developed by Novo Nordisk with a half-life supporting once-weekly subcutaneous dosing (versus pramlintide, the FDA-approved short-acting amylin analog used in diabetes that requires meal-time dosing). See the separate Cagrilintide article for the standalone amylin analog's profile. Semaglutide is the GLP-1 RA already approved as Wegovy (for obesity) and Ozempic (for type 2 diabetes). See the separate Semaglutide article.

Phase 1b Combination Data (Enebo 2021)

The Phase 1b combination data, published by Enebo and colleagues in The Lancet in 2021, established that:

• Cagrilintide and semaglutide could be co-administered safely
• The combination produced greater weight loss than either component alone
• The pharmacokinetics of each component were not significantly altered by co-administration
• Gastrointestinal side effects were the principal tolerability issue, consistent with both components individually

This Phase 1b data motivated the Phase 3 REDEFINE program.

Phase 3 REDEFINE 1 (Obesity Without Diabetes)

REDEFINE 1 was the principal pivotal trial for the obesity indication:

• Design: Phase 3a, 68-week, randomized, double-blind, placebo- and active-controlled
• Population: 3,417 adults with BMI ≥30 kg/m² or BMI ≥27 kg/m² with at least one weight-related medical complication, without diabetes
• Randomization: 21:3:3:7 ratio to CagriSema (n=2,108), semaglutide 2.4 mg alone (n=302), cagrilintide 2.4 mg alone (n=302), or placebo (n=705)
• Setting: lifestyle intervention adjunct in all arms
• Primary endpoint: percent change in body weight at 68 weeks

Results:

Additional efficacy findings:

• Weight loss ≥5%: 97.6% of CagriSema-adherent patients
• Weight loss ≥20%: 60.2%
• Weight loss ≥25%: 40.4%
• Weight loss ≥30%: 23.1%

These response-rate data are particularly notable: more than 40% of adherent patients achieved ≥25% weight loss, a threshold previously associated only with bariatric surgery.

Phase 3 REDEFINE 2 (Obesity with Type 2 Diabetes)

REDEFINE 2 evaluated CagriSema in the T2D population:

• Design: Phase 3a, 68-week, randomized, double-blind, placebo-controlled
• Population: 1,206 adults with BMI ≥27 kg/m² and HbA1c 7-10%, type 2 diabetes
• Randomization: 3:1 CagriSema vs placebo
• Primary endpoint: weight loss and HbA1c reduction at 68 weeks

Results:

• Weight loss: 15.7% with CagriSema vs 3.1% placebo
• HbA1c reduction: substantial, with most patients achieving target HbA1c <7%
• Pattern consistent with REDEFINE 1 but with smaller magnitude of weight loss (typical for T2D obesity trials, where weight loss is generally smaller than in non-diabetic populations)

Falling Short of the 25 Percent Goal

Novo Nordisk had publicly aspired to 25 percent weight loss as a benchmark for CagriSema, positioning it as a category-leading obesity therapy. The actual 22.7% (trial product estimand) and 20.4% (treatment policy estimand) results, while clinically meaningful and superior to semaglutide alone, fell short of this internal target.

The market response when the December 2024 initial readout was released was negative:

• Novo Nordisk stock declined
• Analysts and investors questioned whether CagriSema represented sufficient differentiation from existing options
• Eli Lilly stock (tirzepatide/Zepbound owner) benefited from comparison

This is a meaningful illustration that absolute efficacy magnitude matters as much as relative superiority in the increasingly competitive obesity-drug field.

The Injection-Site Reaction Signal

A notable tolerability finding from REDEFINE 1 was a substantially higher rate of injection-site reactions with CagriSema (12%) compared to semaglutide alone (2.6%). The increase was attributed to the cagrilintide component: 17% of patients on cagrilintide alone reported injection-site reactions. This is a tolerability differentiator versus tirzepatide (which does not show similar injection-site reaction rates).

Other adverse events:

• Gastrointestinal (nausea, vomiting, diarrhea, constipation): common, consistent with GLP-1 RA class effects, mostly mild to moderate
• Discontinuation due to adverse events: low single-digit percentages, comparable to other obesity drug trials
• Pancreatitis, gallbladder events, thyroid concerns: consistent with GLP-1 RA class profile, monitored

REDEFINE Program Beyond 1 and 2

Novo Nordisk's REDEFINE clinical development program extends well beyond the initial REDEFINE 1 and 2 trials:

• REDEFINE 3: Cardiovascular outcomes trial in approximately 7,000 adults with established CVD and obesity. Event-driven, evaluating 3-point MACE. This is the critical study for cardiovascular outcomes labeling.
• REDEFINE 4: Head-to-head comparison versus tirzepatide 15 mg (the FDA-approved comparator from Eli Lilly). 800 participants, 72 weeks. The direct comparison the market is awaiting.
• REDEFINE 5: Weight loss trial in East Asian populations (330 participants, 68 weeks)
• REDEFINE 6: Weight loss trial in Chinese population (300 participants)
• REDEFINE 11: Initiated June 2025, exploring extended treatment duration and re-escalation strategies to potentially achieve >25% weight loss

The pipeline extension reflects Novo Nordisk's commitment to maximizing CagriSema's commercial and clinical positioning.

FDA Submission and Expected Timeline

• December 18, 2025: Novo Nordisk submitted the NDA to the FDA, based on REDEFINE 1 and REDEFINE 2 data
• 2026: FDA review expected
• Late 2026 or early 2027: Potential FDA approval anticipated
• Post-approval: Commercial launch and reimbursement positioning

The NDA submission was for the chronic weight management indication. Type 2 diabetes indication would likely follow as a separate filing or label expansion.

REIMAGINE Program for Type 2 Diabetes

CagriSema is also being investigated in the REIMAGINE program for type 2 diabetes:

• Separate from the REDEFINE program (which is primarily obesity-focused)
• Focus on diabetes-specific endpoints (HbA1c, cardiovascular outcomes, kidney outcomes)
• Less mature data than REDEFINE

Competitive Field

CagriSema enters a rapidly evolving obesity-drug market in 2026:

• Tirzepatide (Zepbound, Eli Lilly): dual GLP-1/GIP RA, approved, ~20-22% weight loss in SURMOUNT trials
• Semaglutide (Wegovy, Novo Nordisk): GLP-1 RA, approved, ~14-16% weight loss in STEP trials
• Retatrutide (Eli Lilly): triple GLP-1/GIP/glucagon RA in Phase 3, very high weight loss (~24% in Phase 2)
• Survodutide (Boehringer Ingelheim/Zealand): GLP-1/glucagon RA in Phase 3
• Orforglipron (Eli Lilly): oral small-molecule GLP-1 RA in Phase 3

CagriSema's positioning depends on its absolute efficacy, tolerability profile (injection-site reactions are a concern), pricing, and FDA labeling. The head-to-head data against tirzepatide from REDEFINE 4 will be the definitive comparison.

Regulatory Status

• FDA: NDA submitted December 18, 2025. Approval expected late 2026 or early 2027.
• EMA: Application timeline parallel to or following FDA
• Not yet approved in any major jurisdiction
• WADA: GLP-1 RA and amylin analogs are not currently prohibited (the class is not WADA-banned as of 2026, though this could change)

CagriSema's mechanism is the complementary action of two distinct gut-brain axis peptides: amylin (via cagrilintide) and GLP-1 (via semaglutide). The combination targets multiple appetite and metabolic pathways simultaneously.

Cagrilintide: Amylin Receptor Mechanism

Cagrilintide is a long-acting amylin analog. It acts on amylin receptors, which are heterodimers of the calcitonin receptor (CTR) and receptor activity-modifying proteins (RAMPs 1, 2, or 3). The three principal amylin receptor subtypes (AMY1, AMY2, AMY3) are differentially expressed in:

• Brainstem area postrema (principal site of amylin satiety action)
• Hypothalamus
• Nucleus accumbens (reward pathways)

Cagrilintide is a dual amylin and calcitonin receptor agonist (DACRA), engaging both amylin receptors and the calcitonin receptor, which expands its pharmacological reach.

Amylin signaling produces:

• Delayed gastric emptying (mechanically extending postprandial satiety)
• Suppression of glucagon (improving glycemic control)
• Brainstem-mediated satiety (reducing meal size)
• Reward-pathway modulation (reducing palatable food preference)
• Reduced food intake in animal and human studies

Semaglutide: GLP-1 Receptor Mechanism

Semaglutide is a long-acting GLP-1 analog. It acts on the GLP-1 receptor, a Gs-coupled GPCR expressed on:

• Pancreatic β-cells (glucose-dependent insulin secretion)
• Pancreatic α-cells (glucagon suppression)
• Gastric smooth muscle (slowed gastric emptying)
• Hypothalamic arcuate nucleus (appetite suppression)
• Brainstem nucleus of the solitary tract (satiety)
• Reward pathways (food reward modulation)

GLP-1 RA signaling produces:

• Increased insulin secretion (glucose-dependent, minimal hypoglycemia risk)
• Decreased glucagon
• Slowed gastric emptying
• Hypothalamic appetite suppression
• Reduced food intake and preference for high-calorie foods

The Synergy

The two systems converge on appetite regulation through different but overlapping pathways:

• GLP-1: primarily hypothalamic satiety + slowed gastric emptying + insulin/glucagon modulation
• Amylin: primarily brainstem area postrema satiety + gastric emptying + glucagon suppression + reward modulation

The combination produces:

• Additive or synergistic appetite suppression
• Enhanced satiety from multiple convergent pathways
• Stronger glycemic improvement than either alone
• Potentially complementary effects on body composition

The clinical synergy was demonstrated in REDEFINE 1: 22.7% combined > 16.1% semaglutide + 11.8% cagrilintide (simple addition would be ~27.9%, so the effect is sub-additive in absolute terms but clearly greater than either alone).

Pharmacokinetics

• Cagrilintide: long half-life supporting once-weekly dosing (similar mechanism to semaglutide's albumin-binding fatty acid side chain modification)
• Semaglutide: half-life approximately 165-184 hours (about 1 week)
• Combination: both components co-formulated in a single fixed-dose injection, once-weekly subcutaneous administration

The synchronized pharmacokinetics (both with weekly dosing) make the fixed-dose combination practical.

Effects in Phase 3 clinical trials (REDEFINE 1 and 2):

• Weight loss (REDEFINE 1, obesity without diabetes, 68 weeks): 22.7% (trial product estimand), 20.4% (treatment policy estimand)
• Response rates (REDEFINE 1, adherent patients): ≥5% weight loss 97.6%, ≥20% 60.2%, ≥25% 40.4%, ≥30% 23.1%
• Weight loss (REDEFINE 2, type 2 diabetes, 68 weeks): 15.7%
• HbA1c reduction (REDEFINE 2): substantial reductions, most patients achieving target <7%
• Waist circumference: significant reductions consistent with weight loss
• Blood pressure: modest reductions
• Lipid parameters: improvements consistent with weight loss
• Quality of life measures: improvements in standardized obesity QoL scales

Effects compared to comparators in REDEFINE 1:

• vs Semaglutide 2.4 mg alone: superior weight loss (22.7% vs 16.1%)
• vs Cagrilintide 2.4 mg alone: superior weight loss (22.7% vs 11.8%)
• vs Placebo: vastly superior (22.7% vs 3.0%)
• vs Tirzepatide (cross-trial only, REDEFINE 4 head-to-head pending): comparable magnitude

Honest evidence framing: CagriSema has produced clinically meaningful and statistically significant weight loss in two large Phase 3 trials with rigorous comparators. The 22.7% weight loss is among the highest observed in Phase 3 obesity trials to date. The data fell short of Novo Nordisk's aspirational 25% benchmark but represent a meaningful advance over semaglutide monotherapy. The tolerability profile is acceptable but includes notable injection-site reactions attributed to the cagrilintide component. The head-to-head comparison with tirzepatide is the critical missing piece of the competitive picture and is awaited from REDEFINE 4. FDA approval is anticipated but not certain.

CagriSema is investigational and not commercially available. All dosing described here is from clinical trial protocols.

Phase 3 trial regimen (REDEFINE 1 and 2):

• Maintenance dose: cagrilintide 2.4 mg + semaglutide 2.4 mg, fixed-dose combination, subcutaneous, once weekly
• Titration: gradual dose escalation over approximately 16 weeks to minimize gastrointestinal tolerability issues
  • Typical escalation pattern: 0.25 mg of each → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg
  • Some flexibility for slower escalation in patients with tolerability issues
• Maintenance phase: 2.4 mg/2.4 mg weekly indefinitely as long as treatment is continued
• Lifestyle adjunct: standardized diet and physical activity counseling

Route: subcutaneous injection in the abdomen, thigh, or upper arm (similar to other GLP-1 RA injection sites)

Dose modifications:

• Slower titration permitted for tolerability
• Submaximal maintenance doses permitted under protocol for patients who could not tolerate full dose
• REDEFINE 1 protocol allowed continuation of submaximal doses if deemed best for patient

Treatment duration:

• 68 weeks in REDEFINE 1 and 2
• Extended duration in REDEFINE 11 to evaluate longer-term efficacy and potential re-escalation strategies
• Expected indefinite use as a chronic weight management therapy (similar to other obesity pharmacotherapy)

Special populations (based on individual component data, since combination-specific data is limited):

• Pregnancy: contraindicated (consistent with GLP-1 RA class and amylin analog labeling)
• Breastfeeding: avoid
• Pediatric: not studied in CagriSema specifically. Semaglutide is FDA-approved for adolescents 12+ separately.
• Personal or family history of medullary thyroid cancer or MEN 2: contraindicated (GLP-1 RA class effect from rodent studies)
• Pancreatitis history: caution
• Severe gastroparesis: caution due to additive gastric emptying delay
• Severe renal or hepatic impairment: dose adjustment data not yet finalized

Access: CagriSema is currently accessible only through enrollment in the ongoing Novo Nordisk REDEFINE clinical trials. It is not available through any pharmacy, compounding facility, or research-chemical channel. Any product marketed as 'CagriSema' outside the official Novo Nordisk clinical program would be unauthorized.

Adverse effects from REDEFINE 1 (Phase 3, 68 weeks):

Gastrointestinal (most common, consistent with GLP-1 RA class):

• Nausea
• Vomiting
• Diarrhea
• Constipation
• Abdominal pain
• Most mild to moderate, occurring primarily during dose escalation
• Diminish over time as patients adapt

Injection-site reactions (notable signal):

• 12% of CagriSema patients reported injection-site reactions
• Compared to 2.6% on semaglutide alone
• 17% on cagrilintide alone
• The signal is attributed to the cagrilintide component
• This is a meaningful tolerability differentiator versus tirzepatide

Other adverse events:

• Headache
• Fatigue
• Dizziness
• Decreased appetite (intended pharmacological effect)
• Mild lipid alterations
• Pancreatitis: rare but monitored as a class effect
• Gallbladder events: monitored as a class effect (cholelithiasis, cholecystitis)
• Increased heart rate (mild)

Discontinuation rates:

• Discontinuation due to adverse events: approximately 1% in CagriSema arm
• Compared to 0.1% in placebo arm
• Low single-digit percentages overall, comparable to other obesity drug Phase 3 trials

Theoretical and class-effect concerns:

• Medullary thyroid carcinoma (MTC): GLP-1 RA class carries a boxed warning based on rodent studies showing C-cell tumor development. Human data has not confirmed an increased risk in monitored cohorts, but the boxed warning remains. CagriSema is expected to carry the same boxed warning.
• Pancreatitis: low absolute incidence but a class concern
• Diabetic retinopathy progression: observed with rapid glycemic improvement on GLP-1 RA (semaglutide). Relevant for patients with pre-existing retinopathy.
• Cardiovascular outcomes: REDEFINE 3 will provide definitive CV outcomes data. The semaglutide component has established CV benefit from SUSTAIN-6 and SELECT trials.
• Renal outcomes: GLP-1 RA class shows renal protective signals. CagriSema-specific data is pending.

Contraindications and cautions:

• Personal or family history of MTC or MEN 2 syndrome
• Pregnancy and breastfeeding
• Severe gastroparesis
• Acute pancreatitis history
• Hypersensitivity to either component

Drug interactions:

• Other GLP-1 RA or amylin analogs: avoid concurrent use (additive effects)
• Insulin and sulfonylureas: may require dose reduction in diabetes due to enhanced glycemic control
• Oral medications with narrow therapeutic windows: slowed gastric emptying may affect absorption
• Warfarin: monitor INR

Long-term safety: REDEFINE 1 and 2 data extend to 68 weeks. REDEFINE 3 cardiovascular outcomes trial and REDEFINE 11 extended-duration trial will provide longer-term data. The semaglutide component has approximately 6+ years of post-marketing safety data through Wegovy and Ozempic.

CagriSema sits at the leading edge of the next-generation GLP-1-class obesity therapeutics. Its closest comparators:

• Cagrilintide: the standalone amylin analog component. Less weight loss than CagriSema but a potential standalone therapy. Same Novo Nordisk pipeline.
• Semaglutide (Wegovy, Ozempic): the standalone GLP-1 RA component. FDA-approved separately. The clinical and commercial precedent.
• Tirzepatide (Zepbound, Mounjaro): the dominant competitor. Dual GLP-1/GIP RA. Similar weight loss magnitude. Different second mechanism. Different injection-site profile. FDA-approved. Head-to-head data with CagriSema pending from REDEFINE 4.
• Retatrutide: Eli Lilly's triple GLP-1/GIP/glucagon RA in Phase 3. Phase 2 data suggests very high weight loss (~24%). Will be a competitor if FDA-approved.
• Survodutide: Boehringer Ingelheim/Zealand GLP-1/glucagon RA in Phase 3. Different second mechanism.
• Orforglipron: Eli Lilly oral small-molecule GLP-1 RA in Phase 3. Oral route is the principal differentiator.
• Pramlintide: the FDA-approved short-acting amylin analog. Used in type 1 and type 2 diabetes. The mechanistic precedent for cagrilintide.

Common stacks circulating in clinical and off-label contexts:

Note: CagriSema itself is not currently available outside Phase 3 trials. The compound cannot be obtained for off-label use as of May 2026. Once approved, it will be a single-product prescription medication, not a stackable peptide.

For semaglutide and cagrilintide individually (which are available separately, though cagrilintide is also investigational):

• Semaglutide alone: established Wegovy regimen, 2.4 mg weekly
• Cagrilintide alone: not yet FDA-approved
• Semaglutide + Lifestyle: standard of care
• GLP-1 RA + Tesamorelin: occasional off-label combination for body composition (different effects)

Combinations to avoid (when CagriSema becomes available):

• Other GLP-1 RAs or amylin analogs: avoid concurrent use. Additive effects with no efficacy benefit and increased side effects
• Pregnancy and breastfeeding: contraindicated
• MTC or MEN 2 history: contraindicated
• Severe gastroparesis: avoid

The most actionable framing of CagriSema in 2026: this is the most advanced GLP-1 + amylin combination in clinical development, with strong Phase 3 efficacy data (22.7% weight loss in REDEFINE 1, 15.7% in REDEFINE 2 with diabetes) that established statistical and clinical superiority to semaglutide monotherapy. The compound fell short of Novo Nordisk's aspirational 25% benchmark, and the injection-site reaction signal is a tolerability concern. FDA approval is anticipated late 2026 or early 2027. CagriSema is currently accessible only through clinical trial enrollment. Once approved, it will compete primarily with tirzepatide for obesity prescription market share. The REDEFINE 4 head-to-head trial versus tirzepatide will be the definitive competitive comparison. Patients interested in CagriSema currently have two options: enroll in an ongoing REDEFINE trial (if eligible), or wait for FDA approval and commercial launch. There is no legitimate way to access CagriSema outside the clinical trial program.

For informational and educational purposes only. Not medical advice. Not for human consumption unless prescribed by a licensed physician for an FDA-approved indication. Consult a qualified healthcare provider before using any peptide or pharmaceutical product.